iBio appoints Martin Brenner as permanent CEO and Felipe Duran as permanent CFO

iBio, Inc.

Martin Brenner, formerly interim CEO and CSO, appointed permanent CEO; Felipe Duran, formerly interim CFO, appointed permanent CFO, effective June 22, 2023.
Brenner's base salary set at $507,150, including prior $7,500/month interim stipend; granted 75,833 RSUs vesting over 7 months.
Duran's compensation unchanged: base salary of $350,000 with 40% target bonus and $140,000 special incentive bonus.
Board expresses confidence in duo to lead iBio's AI-powered antibody discovery platform and next stage of growth.
Brenner has leadership experience at major pharma including Pfizer and Merck; Duran previously VP of FP&A at iBio.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Martin Brenner

Chief Executive Officer

IBIO · iBio, Inc.

Effective: 2023-06-22
Filed: June 27, 2023, 7:59 PM ET

appointed Dr. Martin Brenner its then Interim Chief Executive Officer (CEO), to the position of permanent CEO effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Martin Brenner was appointed as Chief Executive Officer at iBio, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

appointed Dr. Martin Brenner its then Interim Chief Executive Officer (CEO), to the position of permanent CEO effective immediately

View on SEC.gov

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001420720-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.